Research paper
Controlled‐release oral melatonin supplementation for hypertension and nocturnal hypertension: A systematic review and meta‐analysis
Study answer
What this study found
Controlled-release melatonin may modestly lower asleep blood pressure, but the overall antihypertensive effect was inconsistent and evidence certainty was low to very low. In pooled analyses of controlled-release melatonin, asleep SBP fell by -4.67 mm Hg (95% CI: -8.79 to -.55) and asleep DBP by -2.39 mm Hg (95% CI: -5.01 to .23), while daytime SBP and DBP were not significantly changed. Immediate-release melatonin increased 24-h SBP by 6.5 mm Hg (95% CI: 2.3 to 10.7; p < .001) and 24-h DBP by 4.9 mm Hg (95% CI: 1.2 to 8.4; p < .001). Sleep outcomes showed small, non-significant…
- Study & population
- Systematic review and meta-analysis of 4 randomized controlled trials in adults with hypertension or nocturnal hypertension.
- Intervention
- Oral melatonin was studied mainly as controlled-release formulations, with one immediate-release trial.
- Key limitation
- Evidence was based on only 4 short-term trials with 137 participants total, limiting precision and generalizability.
View source
Open PDFOriginal abstract
Oral melatonin is a potential alternative treatment for hypertension and nocturnal hypertension. However, high‐quality and relevant meta‐analyses are lacking. This meta‐analysis aimed to investigate whether oral melatonin supplementation reduces dayt…